Lilly Says Taltz Plus Zepbound Outperformed Taltz Alone in Phase 3b PsA Data
Lilly said 52-week Phase 3b TOGETHER-PsA data showed the combination improved and sustained efficacy.
Lilly said 52-week Phase 3b TOGETHER-PsA data showed the combination improved and sustained efficacy.